FLGT
Fulgent Genetics, Inc. · NASDAQ
- Sector Health Services
- Industry Medical/Nursing Services
- Website fulgentgenetics.com
- Employees(FY) 1012
- ISIN US3596641098
Performance
+3.37%
1W
+4.12%
1M
-4.53%
3M
-0.34%
6M
-30.02%
YTD
-23.34%
1Y
Profile
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Technical Analysis of FLGT 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-09 09:55
- 2024-12-03 19:00
FLGT: Raising target price to $21.00(Argus Research)
- 2024-11-26 19:00
FLGT: Raising target price to $19.00(Argus Research)
- 2024-11-22 12:00
- 2024-11-19 19:16
- 2024-11-12 19:00
FLGT: Lowering target price to $20.00(Argus Research)
- 2024-11-10 08:16
- 2024-11-10 08:01
- 2024-11-09 07:31
- 2024-11-09 02:05
- 2024-11-08 08:15
- 2024-11-08 07:00
Fulgent Reports Third Quarter 2024 Financial Results(Business Wire)
- 2024-11-07 19:40
- 2024-11-07 18:00
Fulgent Reports Third Quarter 2024 Financial Results(Businesswire)
- 2024-11-05 19:00
FLGT: Rating decreased to a HOLD(Argus Research)
- 2024-11-05 08:00
Fulgent to Participate in Upcoming Conferences(Business Wire)
- 2024-11-04 19:00
Fulgent to Participate in Upcoming Conferences(Businesswire)
- 2024-10-31 20:08
- 2024-10-31 08:00
- 2024-10-30 20:00
- 2024-10-17 16:05
- 2024-10-17 04:05
- 2024-10-08 20:00
FLGT: What does Argus have to say about FLGT?(Argus Research)
- 2024-10-08 07:46
- 2024-09-18 09:00
- 2024-08-27 20:00
FLGT: Rating increased to a HOLD(Argus Research)
- 2024-08-20 20:00
FLGT: What does Argus have to say about FLGT?(Argus Research)
- 2024-08-13 12:00
- 2024-08-13 09:55
- 2024-08-02 14:29
Fulgent Genetics Swings to Q2 Earnings, Revenue Rises(MT Newswires)
Page 1 of 7
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.